Catherine Soldano-Noble Executive Director, Marketing & Business Development Medpace, Inc. Cincinnati, OH 45212Amendment #5 to the Letter Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations
Re: Amendment #5 to the Letter Agreement (“Amendment #5”) for certain initial services for the Ethyl-EPA Hypertriglyceridemia Studies between Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, and Medpace, Inc. dated 1 December 2008, as amended on 19 January 2009 and as further amended on 30 January 2009, 5 May 2009 and 3 August 2009 (the “Initial Services Letter Agreement”).
